Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of YH4808
NCT02072447Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YH4808 in gastroesophageal reflux disease (GERD), sponsored by Seoul National University Hospital. Primary endpoint: Absolute bioavailability at 216 hours. Started Mar 2014; status: completed.
02
Drugs
YH4808
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02072447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072447.